Mark - Asabys Partners

Portfolio

June 11, 2026

Oriva Therapeutics appoints Dr Agnès Arbat as CEO to advance clinical-stage women’s health pipeline

READ THIS NEWS IN SPANISH Oriva is developing innovative medicines for chronic gynaecological diseases and…

Mark

Portfolio

June 4, 2026

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

READ THIS NEWS IN SPANISH Oversubscribed Series B financing co-led by new investors Columbus Venture…

Mark

Portfolio

May 20, 2026

Asabys Announces a New Life Sciences Fund Following Its Selection in the CDTI and EIF Innvierte Deep Start Initiative

READ THIS NEWS IN SPANISH Asabys launches a fund of up to €120M to transform…

Mark

Portfolio

May 19, 2026

The Ministry of Science, Innovation and Universities, through CDTI, and the EIF invest €74.7 million in the Asabys Innvierte Tech Transfer fund to boost innovation and company creation in biotechnology and medical technologies

READ THIS NEWS IN SPANISH Second transaction under the Innvierte Deep Start framework, an instrument…

Mark

Portfolio

February 25, 2026

Medasense Appoints MedTech Leader Peter Wehrly as Executive Chairman of the Board

Medasense today announced the appointment of Peter Wehrly as Executive Chairman of the Board. Over…

Mark

Portfolio

January 22, 2026

Orikine Bio appoints Larry Edwards as Chairman of the Board

Orikine Bio, a biotechnology company based at the Barcelona Science Park (PCB-UB), today announced the…

Mark

Portfolio

February 3, 2026

Asabys-backed Oriva Therapeutics launches to advance novel treatments for women’s health

READ THIS NEWS IN SPANISH Oriva Therapeutics is launched with the support of Asabys, focused…

Mark

Portfolio

January 13, 2026

SafeHeal® Announces Successful Launch of SAFE-3CV IDE Study for Colovac® Anastomosis Protection Technology

Breakthrough device promises significantly improved patient recovery after colorectal surgery SafeHeal®, a leading innovator in…

Mark

Portfolio

January 9, 2026

Agomab Announces Positive Phase 1 Interim Results with AGMB-447 in Healthy Participants and Initiation of Idiopathic Pulmonary Fibrosis Cohort

Interim data from Phase 1 with single and multiple ascending doses show no safety signals…

Mark

Portfolio

December 9, 2025

INBRAIN Neuroelectronics Appoints Scott Huennekens as Chairman of the Board

INBRAIN Neuroelectronics, a brain-computer interface therapeutics (BCI-Tx} company developing graphene-based neural technologies, today announced the…

Mark

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others